When it comes to how NWBO can pay for all the growth that's about to happen in the next few years, there's an expression used in multi-level marketing that I believe should apply. Incorporate the work of others.
I can believe that companies, like CRL, will pay for the rights to lease the EDEN and become the CDMO for providing the DCVax's throughout much of the world. I believe Merck will pay much, if not all the costs of running trials that prove the Keytruda has benefits when used with DCVax-L in many solid cancers. I'd not be surprised if NWBO would like to acquire Oncovir in exchange for stock, but not until the price is dramatically higher.
In terms of equity partnerships, I believe that there are BP's who'd be willing to purchase a substantial percentage of NWBO who're willing to pay the $20 or more that LP demands, but not until NWBO's stock price has reached approximately 50% of what they're willing to pay. I'm speaking of billions coming in, but not until the share price is right.
In short, I'm saying that many will pay for the right to work with NWBO, it won't require a huge investment by NWBO in things like production facilities, many trials will be supported by others, etc. Certainly they need to grow, but the growth need not be tremendous as others do the work, and NWBO is paid.
Gary
Bullish
Market Data 
Markets 
AI
